Skip to main content
HLS Therapeutics Inc. logo

HLS Therapeutics Inc. — Investor Relations & Filings

Ticker · HLS ISIN · US40390B3078 LEI · 549300QKXFY1J71L2D68 TSX Wholesale and retail trade
Open in API
Filings indexed 364 across all filing types
Latest filing 2020-06-01 Investor Presentation
Country CA Canada
Listing TSX HLS

About HLS Therapeutics Inc.

https://hlstherapeutics.com/

HLS Therapeutics Inc. is a specialty pharmaceutical company focused on the acquisition and commercialization of branded medicines across North America. The company targets products that address unmet needs, primarily in the treatment of psychiatric disorders and cardiovascular disease/risk reduction. Its commercial-stage portfolio includes CLOZARIL® (clozapine) for psychiatric disorders and VASCEPA® (icosapent ethyl) for cardiovascular risk reduction. HLS also commercializes NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid/ezetimibe combination) for the reduction of LDL-cholesterol in patients at risk of cardiovascular disease. HLS ensures reliable market access to these essential therapies by sourcing products directly from originators and best-in-class manufacturing partners.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Investor Presentation Classification · 90% confidence The document is a short announcement about HLS Therapeutics' CEO presenting at the Jefferies Virtual Healthcare Conference. It includes details about the presentation date, webcast links, and company background. There is no financial data, no report attached or referenced as being published, and no regulatory or voting information. The content is a notification of an upcoming investor presentation event rather than the presentation materials themselves. Therefore, it fits the category of an Investor Presentation announcement or notice. Given the document length is short and it is an announcement of a presentation event, the best classification is Investor Presentation (IP).
2020-06-01 English
News release - English.pdf
Investor Presentation Classification · 90% confidence The document is a short announcement (1700 characters) about HLS Therapeutics' CEO presenting at the Jefferies Virtual Healthcare Conference. It includes details about the presentation date, time, and webcast links. There is no financial data, no detailed report, no voting results, no management changes, or other regulatory filings. It is essentially an investor presentation announcement but does not contain the presentation itself. Given the short length and nature of the content, it fits best as an Investor Presentation (IP) announcement rather than the full presentation document. Therefore, the classification is Investor Presentation (IP) with high confidence.
2020-06-01 English
News release - English.pdf
Regulatory Filings
2020-06-01 English
Other.pdf
AGM Information Classification · 95% confidence The document is a Voting Instruction Form (VIF) for the Annual General Meeting (AGM) of HLS Therapeutics Inc. scheduled for June 19, 2020. It contains instructions for shareholders on how to vote, appoint proxies, and details about the meeting agenda such as election of directors and reappointment of auditors. It also includes information on how to receive interim and annual financial statements. The content is focused on proxy voting and shareholder instructions rather than the actual AGM materials or presentations. Therefore, this document is best classified as AGM Information (AGM-R), which covers presentations and materials shared during the AGM or related proxy materials.
2020-05-22 English
Management information circular - English.pdf
Proxy Solicitation & Information Statement Classification · 95% confidence The document is titled as a "Notice of Annual Meeting of Shareholders" and includes a "Management Information Circular" dated May 19, 2020. It details the agenda for the annual meeting scheduled for June 19, 2020, including election of directors, reappointment of auditors, and other shareholder meeting matters. It also provides detailed instructions on how shareholders can vote, including proxy voting procedures. The document contains governance-related information such as election of directors, auditor reappointment, governance practices, and executive compensation. This type of document is typically classified as Proxy Solicitation & Information Statement (PSI), as it is sent to shareholders to provide information and request votes for the annual meeting. It is not the Annual Report (10-K) or the actual financial statements, but rather the proxy materials related to the AGM. The document length (15,000 characters) and content confirm it is a full proxy circular, not just a brief announcement or notice. Therefore, the appropriate classification is PSI with high confidence.
2020-05-22 English
Notice of meeting - English.pdf
AGM Information Classification · 95% confidence The document is a Notice of Annual Meeting of Shareholders for HLS Therapeutics Inc. It details the date, location, and agenda of the annual meeting, including receiving audited financial statements, electing directors, and reappointing auditors. It also provides instructions for proxy voting and mentions COVID-19 related attendance considerations. The document does not contain the actual annual report or financial statements but serves as a formal notification to shareholders about the meeting and voting procedures. Therefore, it is classified as AGM Information (AGM-R). The document length is 5182 characters, which is consistent with a detailed notice rather than a full report.
2020-05-22 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.